ALL THE NEWS
Encounter confirms and extends BM1 copper
/in The Drill Sergeant /by Wally GrahamTHE DRILL SERGEANT: Encounter Resources (ASX: ENR) announced results from ongoing drilling being carried out at the company’s Yeneena project in Western Australia. Exploration is being conducted at the BM1 and BM7 prospects as part of an earn-agreement with global copper miner Antofagasta. “The shallow RC drill program has exceeded our expectations with the near […]
Metals of Africa identifies new Rio Mazoe targets
/in The Drill Sergeant /by Wally GrahamTHE DRILL SERGEANT: Metals of Africa (ASX: MTA) has identified three new high-priority base metals targets at the company’s Rio Mazoe project, in the Tete province of Mozambique. The company said it had identified the three new targets using a combination of interpretation of geological, geochemical and geophysical datasets plus detailed geological mapping, at the […]
Ethics approval granted for OncoSil™ Clinical Pivotal Trial
/in Uncategorized /by Wally GrahamTHE ROADHOUSE PHARMACY: OncoSil Medical Limited (ASX: OSL) has been granted Ethics Approval for the Australian hospital sites for the Pivotal Clinical Trial for the company’s lead product candidate, the OncoSil™ localised radiation therapy treatment for pancreatic cancer. The company said the Ethics Approval for the Australian sites in the OncoSil™ Pivotal Clinical Trial was […]
Thundelarra hits DSO grade copper at Red Bore
/in The Drill Sergeant /by Wally GrahamTHE DRILL SERGEANT: Thundelarra (ASX: THX) released results of two recently-completed diamond drill holes at the company’s 90 per cent-owned Red Bore prospect (M52/597) in Western Australia’s Doolgunna region and practically doubled its share price. The company said the holes were designed to help define the geometry and to increase the known extent of brecciated […]
Kibaran encounters big numbers at Epanko
/in The Drill Sergeant /by Wally GrahamTHE DRILL SERGEANT: Kibaran Resources (ASX: KNL) has received results from a recent Reverse Circulation (RC) drill program carried out at the Epanko deposit within the company’s Mahenge graphite project in Tanzania. The company claims the drilling has returned the best graphite intersections it has encountered to date with all drill holes intersecting high-grade, premium […]
Pioneer identifies new Dingo Dam prospect
/in The Drill Sergeant /by Wally GrahamTHE DRILL SERGEANT: Pioneer Resources (ASX: PIO) has carried out interpretation of soil geochemistry results and field reconnaissance at the company’s 100 per cent-owned Juglah Dome project, located just outside of Kalgoorlie in Western Australia. The program resulted in the identification of a new polymetallic anomaly, which Pioneer said will be referred to as the […]
Cynata Contracts Leading CRO to Conduct Preclinical Studies
/in Uncategorized /by Wally GrahamTHE ROADHOUSE PHARMACY: Cynata Therapeutics (ASX: CYP) has signed an agreement with WuXi AppTec (NYSE:WX), a leading global biopharmaceutical contract research organisation, to conduct preclinical safety studies with Cynata’s unique Cymerus™ stem cell technology. The studies will be conducted at WuXi AppTec’s GLP-compliant, FDA-registered facility in St Paul, Minnesota. Cynata’s preclinical program has been designed […]
Probiotec commences clinical trial
/in Uncategorized /by Wally GrahamTHE ROADHOUSE PHARMACY: Probiotec Limited (ASX: PBP) announced that further to its ongoing research and development program with Griffith University and other research organisations, the company has commenced a clinical trial to investigate the effectiveness of Glycomax Lactoferrin and bovine whey derived Ig rich fraction (Immunoglobulin) for the treatment of atopic dermatitis. The study will […]
FDA grants Starpharma Phase 3 trial
/in Uncategorized /by Wally GrahamTHE ROADHOUSE PHARMACY: Starpharma Holdings (ASX: SPL) announced the US Food and Drug Administration (FDA) has granted Special Protocol Assessment (SPA) agreement on the design and planned analyses of the phase 3 clinical studies of the VivaGel® bacterial vaginosis (BV) product for the prevention of recurrent BV. Starpharma said the favourable SPA outcome provides a […]
Neuren to start Phase 2 trial
/in Uncategorized /by Wally GrahamTHE ROADHOUSE PHARMACY: Neuren Pharmaceuticals (ASX: NEU) has received approval from the Institutional Review Board at Womack Army Medical Centre to start its Phase 2 clinical trial of NNZ-2566 in concussion (also referred to as mild traumatic brain injury). The double-blind, placebo-controlled trial will be conducted with the US Army’s 82nd Airborne Division at Fort […]